Related Experiment Video
Updated: Jun 5, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
Carbimazole embryopathy: implications for the choice of antithyroid drugs in pregnancy
P Bowman1, N J Osborne, R Sturley
1Department of Paediatrics, Royal Devon & Exeter Hospital, Exeter, UK. pamelabowman@nhs.net
Abstract:
Maternal thyrotoxicosis, predominantly secondary to Graves' disease, affects 0.2% of all pregnancies. The Endocrine Society guidelines recommend the use of propylthiouracil as a first-line drug for thyrotoxicosis in pregnancy because of associations between carbimazole or methimazole and congenital anomalies. However, recent studies have highlighted the risk of severe liver injury with propylthiouracil. Here, we report another case with multiple congenital anomalies following in utero exposure to carbimazole and review the literature to consider the risks and benefits of available pharmacological treatments for thyrotoxicosis in pregnancy.
Related Concept Videos
Teratogenicity
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Intrauterine Drug Delivery Systems
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Graves' Disease I: Introduction